Abstract
BackgroundAnti-topoisomerase antibodies (ATA) in systemic sclerosis (SSc) have been associated with poorer prognosis including diffuse skin involvement, pulmonary fibrosis, cardiac involvement and increased mortality. However, 30–60% of ATA-positive SSc patients...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have